Publication of EGM Circular

RNS Number : 9081C

Syncona Limited

04 October 2018

 

Syncona Limited

Publication of EGM Circular to amend investment policy

04 October 2018

Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, has today published a circular outlining a proposal to approve changes to the Investment Policy. The proposed changes would provide the Company with greater flexibility to support our life science portfolio companies and maximise investment returns for our shareholders.

Details of the proposed changes to the Investment Policy, the background to those changes, and the notice of an extraordinary general meeting ("EGM") to seek approval of a Special Resolution to approve the proposed changes are set out in the circular (the "EGM Circular"). The EGM will be held on 30^th October 2018 at 10.30a.m.

The EGM Circular, together with the Form of Proxy for use at the EGM, is available electronically on Syncona's website and can be found here: https://www.synconaltd.com/investors/document-library/. Printed copies of these documents are also being posted to shareholders where requested.

In compliance with Listing Rule 9.6.1, the EGM Circular has today been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

 [ENDS]

Enquiries

Syncona Ltd

Annabel Clay

Tel: [phone]

Tulchan Communications

Martin Robinson

Lisa Jarrett-Kerr

Tel: [phone]

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com 

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

 

END

 

 

MSCFSAFMDFASEIS